415 related articles for article (PubMed ID: 26019408)
1. Toxic species in amyloid disorders: Oligomers or mature fibrils.
Verma M; Vats A; Taneja V
Ann Indian Acad Neurol; 2015; 18(2):138-45. PubMed ID: 26019408
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
[TBL] [Abstract][Full Text] [Related]
3. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits.
Stefani M
Prog Neurobiol; 2012 Dec; 99(3):226-45. PubMed ID: 22450705
[TBL] [Abstract][Full Text] [Related]
4. Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases.
Kreutzer AG; Nowick JS
Acc Chem Res; 2018 Mar; 51(3):706-718. PubMed ID: 29508987
[TBL] [Abstract][Full Text] [Related]
5. Structural fingerprints and their evolution during oligomeric vs. oligomer-free amyloid fibril growth.
Foley J; Hill SE; Miti T; Mulaj M; Ciesla M; Robeel R; Persichilli C; Raynes R; Westerheide S; Muschol M
J Chem Phys; 2013 Sep; 139(12):121901. PubMed ID: 24089713
[TBL] [Abstract][Full Text] [Related]
6. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic species in amyloid-associated diseases: Oligomers or mature fibrils.
Siddiqi MK; Malik S; Majid N; Alam P; Khan RH
Adv Protein Chem Struct Biol; 2019; 118():333-369. PubMed ID: 31928731
[TBL] [Abstract][Full Text] [Related]
8. Influence of the β-sheet content on the mechanical properties of aggregates during amyloid fibrillization.
Ruggeri FS; Adamcik J; Jeong JS; Lashuel HA; Mezzenga R; Dietler G
Angew Chem Int Ed Engl; 2015 Feb; 54(8):2462-6. PubMed ID: 25588987
[TBL] [Abstract][Full Text] [Related]
9. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies.
Bigi A; Cascella R; Cecchi C
Neural Regen Res; 2023 Nov; 18(11):2332-2342. PubMed ID: 37282450
[TBL] [Abstract][Full Text] [Related]
11. Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways.
Ladiwala AR; Dordick JS; Tessier PM
J Biol Chem; 2011 Feb; 286(5):3209-18. PubMed ID: 21098486
[TBL] [Abstract][Full Text] [Related]
12. Conformation-dependent scFv antibodies specifically recognize the oligomers assembled from various amyloids and show colocalization of amyloid fibrils with oligomers in patients with amyloidoses.
Zhang X; Sun XX; Xue D; Liu DG; Hu XY; Zhao M; Yang SG; Yang Y; Xia YJ; Wang Y; Liu RT
Biochim Biophys Acta; 2011 Dec; 1814(12):1703-12. PubMed ID: 21979582
[TBL] [Abstract][Full Text] [Related]
13. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
Takahashi T; Mihara H
Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
[TBL] [Abstract][Full Text] [Related]
14. Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathway.
Lee S; Fernandez EJ; Good TA
Protein Sci; 2007 Apr; 16(4):723-32. PubMed ID: 17327396
[TBL] [Abstract][Full Text] [Related]
15. Screening Carbon Nano Materials for preventing amyloid protein aggregation by adopting a facile method.
Wilson DL; Carreon A; Chinnam S; Sharifan H; Ahlawat J; Narayan M
Res Sq; 2024 Mar; ():. PubMed ID: 38585783
[TBL] [Abstract][Full Text] [Related]
16. Screening Carbon Nano Materials for Preventing Amyloid Protein Aggregation by Adopting a Facile Method.
Wilson DL; Carreon A; Chinnam S; Sharifan H; Ahlawat J; Narayan M
Cell Biochem Biophys; 2024 May; ():. PubMed ID: 38802601
[TBL] [Abstract][Full Text] [Related]
17. Applications of Mass Spectrometry in the Onset of Amyloid Fibril Formation: Focus on the Analysis of Early-Stage Oligomers.
Hu J; Zheng Q
Front Chem; 2020; 8():324. PubMed ID: 32432078
[TBL] [Abstract][Full Text] [Related]
18. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
Matsuzaki K
Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
[TBL] [Abstract][Full Text] [Related]
19. Amyloid Disassembly: What Can We Learn from Chaperones?
Almeida ZL; Brito RMM
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552032
[TBL] [Abstract][Full Text] [Related]
20. Hsp104 targets multiple intermediates on the amyloid pathway and suppresses the seeding capacity of Abeta fibrils and protofibrils.
Arimon M; Grimminger V; Sanz F; Lashuel HA
J Mol Biol; 2008 Dec; 384(5):1157-73. PubMed ID: 18851977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
